GYNECOLOGIC CANCERS

In an interview with Targeted Oncology, Katelyn Handley, MD, discussed two studies on ovarian cancer subtypes and the use of a frailty index to determine patient outcomes before, during, and after ovarian cancer debulking surgery.

A patient with ovarian cancer has begun treatment with oral endoxifen, an active metabolite of tamoxifen, after a Safe to Proceed Letter was granted by the FDA, according to a press release by Atossa Therapeutics, Inc.

The FDA has accepted a biologics license application and granted it a priority review for tisotumab vedotin for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.

In women with advanced epithelial ovarian cancer treated in a single-institution study at the Cleveland Clinic, the addition of paclitaxel to cisplatin for hyperthermic intraperitoneal chemotherapy during interval debulking surgery was associated with improved oncologic outcomes compared with cisplatin alone.

No statistically significant difference was seen with the combination of olaparib and cediranib compared to cediranib alone in patients with recurrent, metastatic or persistent endometrial cancer.

Data from the KEYNOTE-158 study, presented at the Society of Gynecological Oncology 2021 Virtual Annual Meeting on Women’s Cancer, showed durable responses in heavily pretreated patients with vulvar squamous cell carcinoma regardless of their PD-L1 status.

Patients with advanced or recurrent endometrioid endometrial cancer had promising clinical outcomes following treatment with the combination of enzalutamide and carboplatin plus paclitaxel in the phase 2 ENPAC clinical trial.

Niraparib administered as maintenance therapy showed clinical benefit lasting beyond first progression in patients with platinum-sensitive recurrent ovarian cancer with or without germline BRCA mutations, according to the final results of the ENGOT-OV16/NOVA study.

Olaparib maintenance continues to show clinical activity in platinum-sensitive ovarian cancer, including in patients with somatic BRCA mutations and non-BRCA homologous recombination repair mutations.

In a phase 2 trial treatment with eribulin led to disease control and a favorable safety profile among patients with recurrent or advanced cervical cancer.

At the Society of Gynecological Oncology Virtual Annual Meeting on Women’s Cancer data from the phase II OVARIO study continued to show the progression free survival benefit for heavily pretreated patients with advanced ovarian cancer.

Shannon Westin, MD, MPH, FACOG, discusses the rationale of using durvalumab, a PD-L1 inhibitor, with or without olaparib.

Progression-free survival and overall survival were improved with pembrolizumab and lenvatinib when compared with chemotherapy in patients with advanced endometrial cancer who had received prior platinum-based chemotherapy in the phase 3 Study-309/KEYNOTE-775 trial.

CA-125 surveillance alone could be used to detect disease progression in patients with advanced ovarian cancer and an abnormal CA-125 level at the beginning of frontline maintenance therapy with olaparib (Lynparza) and bevacizumab (Avastin), according to an analysis from the phase 3 PAOLA-1 that was presented at the SGO 2021 Annual Meeting on Women’s Cancer.

Compared with standard-of-care chemotherapy, treatment with the PARP inhibitor rucaparib led to a significant prolongation of progression-free survival and improved duration of response in patients with BRCA-mutated advanced, relapsed ovarian cancer, according to primary results from the phase 3 ARIEL4 trial.

Data from a post hoc analysis of the PRIMA/ENGOT-OV26/GOG-3012 phase III trial showed the efficacy of niraparib maintenance therapy for patients with ovarian cancer who had interval debulking surgery or visible residual disease.

A phase 3 trial for cemiplimab monotherapy in comparison with chemotherapy in patients with recurrent or metastatic cervical cancer who previously received chemotherapy treatment is being stopped early due to a unanimous recommendation by the Independent Data Monitoring Committee due to positive overall survival results.

The FDA has accepted a New Drug Application for pafolacianine sodium injection and granted it Priority Review as a potential adjunct for identifying ovarian cancer during surgery.

Shana Wingo, MD, talks about the challenges of treating patients in the Greater Phoenix, Arizona area.

A novel DNA-mediated interleukin-12 immunotherapy, GEN-1, had been granted a Fast Track designation by the FDA for the treatment of advanced ovarian cancer.

The team of oncologic professionals at New Jersey’s only NCI-Designated Comprehensive Cancer Center, Rutgers Cancer Institute, has been expanded to include a new chief of gynecologic oncology.

A Biologics License Application was submitted to the FDA for tisotumab vedotin as treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.

Investigators treating patients with gynecologic malignancies are optimistic that multiple clinical trials exploring new second-line cervical cancer treatments will result in a much-anticipated breakthrough for the field.

Noelle G. Cloven, MD, discussed the current cervical cancer treatment paradigm, the unmet needs that still remain to be addressed, and encouraging new directions of research in clinical trials in honor of Cervical Cancer Awareness Month.

VGX-3100, a therapeutic DNA vaccine, achieved a 25% reduction or more reduction in HPV-16/18-associated vulvar high-grade squamous intraepithelial lesion in 63% of patients at 6 months after treatment with the agent, according to findings from an open-label phase 2 clinical trial.

During a Targeted Oncology Case Based Peer Perspectives event, Bradley Monk, MD, discussed how the use of molecular testing can improve treatment decisions for ovarian cancer.

During a Targeted Oncology Case Based Peer Perspectives event, John K. Chan, MD, reviewed the case of a 49-year-old African American woman with high-grade epithelial ovarian cancer.

Thomas C. Krivak, MD, interpreted the results clinical trials of bevacizumab as treatment of patients with ovarian cancer to determine the optimal treatment strategy for a 69-year-old patient.

Treatment with rucaparib led to an improvement in investigator-assessed progression-free survival compared with chemotherapy in patients with relapsed ovarian cancer with a BRCA mutation who have received 2 or more prior lines of chemotherapy, meeting the primary end point of the phase 3 ARIEL4 clinical trial.

Pembrolizumab plus lenvatinib induced a statistically significant and clinically meaningful improvement in overall survival, progression-free survival, and objective response rate compared with chemotherapy in patients with advanced endometrial cancer after prior systemic therapy in the phase 3 KEYNOTE-775/Study 309 trial.